Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

SAR405838 is a potent and specific MDM2 inhibitor currently being evaluated in Phase I clinical trials for the treatment of human cancer. Using the SJSA-1 osteosarcoma cell line which harbors an amplified MDM2 gene and wild-type p53, we have investigated the acquired resistance mechanisms both in vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman-Luca, C. Gianna, Yang, Chao-Yie, Lu, Jianfeng, Ziazadeh, Daniel, McEachern, Donna, Debussche, Laurent, Wang, Shaomeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466389/
https://www.ncbi.nlm.nih.gov/pubmed/26070072
http://dx.doi.org/10.1371/journal.pone.0128807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466389/
https://www.ncbi.nlm.nih.gov/pubmed/26070072
http://dx.doi.org/10.1371/journal.pone.0128807

Ejemplares similares